Obviously Dr Kaufmann has reviewed all the preclinical Glutamate and GABA data in the Fragile X, Infantile Spasms and Angelman's and is excited that the preclinical finding translated to Humans in the RETT trial. One would expect those biomarkers to translate into the other neurodevelopmental Human trials as well.
For Anavex this little RETT trial could translate into a multibillion Market Cap for the neurodevelopmental indications alone as the Market and other scientists accept and recognize this watershed event.
Anavex kept this as a secret until now. Behold the beauty of "The Pearl of Inestmateable Value" soon to be on display for all to see.
News 
Market Data 
Discover 
